<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03732703</url>
  </required_header>
  <id_info>
    <org_study_id>MyDRUG (MMRC-085)</org_study_id>
    <nct_id>NCT03732703</nct_id>
  </id_info>
  <brief_title>Myeloma-Developing Regimens Using Genomics (MyDRUG)</brief_title>
  <acronym>MyDRUG</acronym>
  <official_title>Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multiple Myeloma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Multiple Myeloma Research Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted&#xD;
      to affect specific genes that are mutated as part of the disease. Mutations in genes can lead&#xD;
      to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of&#xD;
      the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled&#xD;
      to one of the treatment arms. These arms have treatments specifically directed to the mutated&#xD;
      genes. Patients that do not have a greater than 25% mutation to the genes listed can be&#xD;
      enrolled to a non-actionable treatment arm.&#xD;
&#xD;
      The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002&#xD;
      study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related&#xD;
      Plasma Cell Malignancies. (NCT02884102).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll 228 patients enrolled to one of eight treatment arms. The study is open&#xD;
      to patients relapsing with relapsed refractory multiple myeloma, who have&#xD;
&#xD;
        -  received at least one prior but no more than 3 prior therapies&#xD;
&#xD;
        -  exposed to both a PI and an IMiD&#xD;
&#xD;
        -  had early relapse after initial treatment. Relapse is defined as the IMWG uniform&#xD;
           response criteria (Kumar et al, 2016). Early relapse as defined by at least one of the&#xD;
           following:&#xD;
&#xD;
             1. Relapse within 3 years post autologous stem cell transplantation (ASCT) on&#xD;
                maintenance, or 18 months if unmaintained&#xD;
&#xD;
             2. Relapse within 18 months of initial non-ASCT based therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">February 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eight Arms with 38 patients per arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate - Actionable Genetic Alteration</measure>
    <time_frame>Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years</time_frame>
    <description>• To evaluate the overall response rate (ORR) with targeted agents used in combination with backbone regimen ixazomib, pomalidomide and dexamethasone (IPd) in patients with an actionable genetic alteration per the International Myeloma Working Group [IMWG] consensus criteria (Kumar et al, 2016)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate - Non-Actionable Genetic Alteration</measure>
    <time_frame>Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years</time_frame>
    <description>• To evaluate the ORR with agents used in combination with backbone (or IPd) regimen in patients with no actionable genetic alteration per IMWG consensus criteria (Kumar et al, 2016).</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Relapsed Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Sub-Protocol A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Protocol B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with IDH2 activating mutation receive Enasidenib in combination with ixazomib, pomalidomide and dexamethasone (IPd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Protocol C1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with the presence of RAF/RAS mutation receive Cobimetinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Protocol D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with presence of FGFR3 activating mutations receive Erdafitinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Protocol E1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Protocol Y1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Non-Actionable Genetic Abnormality receive Daratumumab in combination with ixazomib, pomalidomide and dexamethasone (IPd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Protocol Y2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Non-Actionable Genetic Abnormality receive Belantamab mafodotin in combination with ixazomib, pomalidomide and dexamethasone (IPd)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sub-Protocol Y3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Non-Actionable Genetic Abnormality receive Selinexor in combination with ixazomib, pomalidomide and dexamethasone (IPd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib, dexamethasone, ixazomib, pomalidomide</intervention_name>
    <description>Patients with relapsed Multiple Myeloma will receive Abemaciclib and Dexamethasone for the first 2 cycles. Abemaciclib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.</description>
    <arm_group_label>Sub-Protocol A1</arm_group_label>
    <other_name>abemaciclib: Verzenio, LY2835219</other_name>
    <other_name>ixazomib: Ninlaro, MLN2238</other_name>
    <other_name>pomalidomide: Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enasidenib, dexamethasone, ixazomib, pomalidomide</intervention_name>
    <description>Patients with relapsed Multiple Myeloma will receive Enasidenib and Dexamethasone for the first 2 cycles. Enasidenib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.</description>
    <arm_group_label>Sub-Protocol B1</arm_group_label>
    <other_name>enasidenib: AG221, IDHIFA</other_name>
    <other_name>ixazomib: Ninlaro, MLN2238</other_name>
    <other_name>pomalidomide: Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cobimetinib, dexamethasone, ixazomib, pomalidomide</intervention_name>
    <description>Patients with relapsed Multiple Myeloma will receive Cobimetinib and Dexamethasone for the first 2 cycles. Cobimetinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.</description>
    <arm_group_label>Sub-Protocol C1</arm_group_label>
    <other_name>cobimetinib: Cotellic, GDC-0973, RG7420</other_name>
    <other_name>ixazomib: Ninlaro, MLN2238</other_name>
    <other_name>pomalidomide: Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erdafitinib, dexamethasone, ixazomib, pomalidomide</intervention_name>
    <description>Patients with relapsed Multiple Myeloma will receive Erdafitinib and Dexamethasone for the first 2 cycles. Erdafitinib, Dexamethasone, Ixazomib and Pomalidomide from cycle 3 forward. Each cycle is 28 days long.</description>
    <arm_group_label>Sub-Protocol D1</arm_group_label>
    <other_name>erdafitinib: G-024, JNJ-42756493, JNJ-493</other_name>
    <other_name>ixazomib: Ninlaro, MLN2238</other_name>
    <other_name>pomalidomide: Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax, dexamethasone, ixazomib, pomalidomide</intervention_name>
    <description>Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.</description>
    <arm_group_label>Sub-Protocol E1</arm_group_label>
    <other_name>venetoclax: Venclexta: ABT-199</other_name>
    <other_name>ixazomib: Ninlaro, MLN2238</other_name>
    <other_name>pomalidomide: Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab, dexamethasone, ixazomib, pomalidomide</intervention_name>
    <description>Patients with relapsed Multiple Myeloma will receive Daratumumab, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.</description>
    <arm_group_label>Sub-Protocol Y1</arm_group_label>
    <other_name>daratumumab: Darzalex</other_name>
    <other_name>ixazomib: Ninlaro, MLN2238</other_name>
    <other_name>pomalidomide: Pomalyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide</intervention_name>
    <description>Patients with relapsed Multiple Myeloma will receive Belantamab mafodotin, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.</description>
    <arm_group_label>Sub-Protocol Y2</arm_group_label>
    <other_name>Belantamab mafodotin: BLENREP, GSK2857916</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor, dexamethasone, ixazomib, pomalidomide</intervention_name>
    <description>Patients with relapsed Multiple Myeloma will receive Selinexor, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.</description>
    <arm_group_label>Sub-Protocol Y3</arm_group_label>
    <other_name>Selinexor: XPOVIO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willing to be registered into the pomalidomide (POMALYST®) Risk Evaluation and&#xD;
             Mitigation Strategy (REMS®) program&#xD;
&#xD;
          -  Enrolled in the MMRF002 Molecular Profiling Protocol (NCT02884102) with report less&#xD;
             than 120 days old&#xD;
&#xD;
          -  Disease free of prior malignancies for ≥ 3 years with exception of currently treated&#xD;
             basal cell, squamous cell carcinoma of the skin, carcinoma &quot;in situ&quot; of the cervix or&#xD;
             breast, or prostate cancer not requiring therapy&#xD;
&#xD;
          -  High risk patients with relapsed refractory multiple myeloma (RRMM), who have:&#xD;
&#xD;
               -  received at least one prior but no more than 3 prior therapies&#xD;
&#xD;
               -  exposed to both a PI and an IMiD&#xD;
&#xD;
               -  had early relapse after initial treatment Early relapse as defined by at least&#xD;
                  one of the following: (Relapse is defined as the IMWG uniform response)&#xD;
&#xD;
                    1. Relapse within 3 years of initiation of induction chemo therapy for post&#xD;
                       autologous stem cell transplantation (ASCT) followed by maintenance, or 18&#xD;
                       months if unmaintained after ASCT&#xD;
&#xD;
                    2. Within 18 months of initial non-ASCT based therapy&#xD;
&#xD;
          -  Patients must have progressed after their most recent treatment and require therapy&#xD;
             for myeloma&#xD;
&#xD;
          -  Females of reproductive potential must have a negative pregnancy test at baseline, be&#xD;
             non-lactating, and willing to adhere to scheduled pregnancy testing&#xD;
&#xD;
          -  Females of reproductive potential and males must practice and acceptable method of&#xD;
             birth control&#xD;
&#xD;
          -  Laboratory values obtained ≤ 14 days prior to registration:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000/ul&#xD;
&#xD;
               -  Hemoglobin (Hgb) ≥ 8 g/dl&#xD;
&#xD;
               -  Platelet (PLT) ≥ 75,000/ul&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 x upper limit of normal (ULN) or if total bilirubin is &gt;1.5&#xD;
                  x ULN, the direct bilirubin must be ≤ 2.0 mg/dL&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) &lt;3 x ULN&#xD;
&#xD;
               -  Creatinine Clearance ≥ 30 mL/min&#xD;
&#xD;
        Measurable disease of Multiple Myeloma (MM) as defined by at least one of the following:&#xD;
&#xD;
          -  Serum monoclonal protein ≥ 0.5 g by protein electrophoresis&#xD;
&#xD;
          -  ≥200 mg of monoclonal protein in the urine on 24-hour electrophoresis&#xD;
&#xD;
          -  Serum immunoglobulin free light chain (FLC) ≥10 mg/dL AND abnormal serum&#xD;
             immunoglobulin kappa to lambda FLC ratio&#xD;
&#xD;
          -  Monoclonal bone marrow plasmacytosis ≥30% (evaluable disease)&#xD;
&#xD;
               -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1, or 2&#xD;
&#xD;
               -  Ability to take aspirin, warfarin, or low molecular weight heparin&#xD;
&#xD;
        Sub-Protocol Inclusion Criteria:&#xD;
&#xD;
        Refer to each respective Sub Protocol for additional inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be ineligible for this study if they meet any one of the following criteria:&#xD;
&#xD;
          -  Aggressive multiple myeloma requiring immediate treatment as defined by:&#xD;
&#xD;
               -  Lactate dehydrogenase (LDH) &gt; 2 times ULN&#xD;
&#xD;
               -  Presence of symptomatic extramedullary disease or central nervous system&#xD;
                  involvement&#xD;
&#xD;
               -  Hypercalcemia &gt;11.5 mg/dl&#xD;
&#xD;
               -  Acute worsening of renal function (CrCl &lt; 30 ml/min) directly related to myeloma&#xD;
                  relapse&#xD;
&#xD;
               -  Any neurological emergency related to myeloma&#xD;
&#xD;
               -  Clinical symptoms of hyperviscosity related to monoclonal protein&#xD;
&#xD;
               -  Involved serum free light chain &gt; 100 mg/dL (1000 mg/L) in the setting of prior&#xD;
                  diagnosis of cast nephropathy&#xD;
&#xD;
          -  Infection requiring systemic antibiotic therapy or other serious infection within 14&#xD;
             days of enrolment&#xD;
&#xD;
          -  Known hypersensitivity or development of erythema nodosum if characterized by a&#xD;
             desquamating rash while taking thalidomide, lenalidomide, pomalidomide or similar&#xD;
             drug. Known allergy to any of the study medications, their analogues, or excipients in&#xD;
             the various formulations of the agents&#xD;
&#xD;
          -  Prior Ixazomib/Pomalidomide/Dexamethasone combination therapy&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Serious medical or psychiatric illness, active alcoholism, or drug addiction that may&#xD;
             hinder or confuse compliance, interfere in the completion of treatment per protocol,&#xD;
             or follow-up evaluation&#xD;
&#xD;
          -  Active hepatitis A, B or C viral infection or known human immunodeficiency virus (HIV)&#xD;
             infection&#xD;
&#xD;
          -  Concurrent symptomatic amyloidosis or plasma cell leukemia&#xD;
&#xD;
          -  POEMS syndrome [plasma cell dyscrasia with polyneuropathy, organomegaly,&#xD;
             endocrinopathy, monoclonal protein (M-protein) and skin changes]&#xD;
&#xD;
          -  Residual side effects to previous therapy &gt; Grade 1 prior to initiation of therapy&#xD;
             (Alopecia any grade and/or neuropathy Grade 2 without pain are permitted)&#xD;
&#xD;
          -  Prior allogeneic or ASCT within 12 weeks of initiation of therapy. Prior allogeneic&#xD;
             stem cell transplant with active graft-versus-host disease (GVHD)&#xD;
&#xD;
          -  Prior experimental therapy within 14 days of protocol treatment or 5 half-lives of the&#xD;
             investigational drug, whichever is longer&#xD;
&#xD;
          -  Prior anticancer therapy within 14 days of initiation of protocol therapy&#xD;
             (Dexamethasone/ 40mg/day) for a maximum of 4 days before screening is allowed&#xD;
&#xD;
          -  Prior major surgical procedure or radiation therapy within 4 weeks of the initiation&#xD;
             of therapy (this does not include limited course of radiation used for management of&#xD;
             bone pain within 7 days of initiation of therapy).&#xD;
&#xD;
          -  Known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that&#xD;
             limit the ingestion or Gastro Intestinal (GI) absorption of drugs administered orally&#xD;
&#xD;
          -  Evidence of current uncontrolled cardiovascular conditions, including uncontrolled&#xD;
             hypertension, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure,&#xD;
             unstable angina, or myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Other co-morbidity, which would interfere with patient's ability to participate in&#xD;
             trial or that confounds the ability to interpret data from the study&#xD;
&#xD;
        Sub-Protocol Exclusion Criteria:&#xD;
&#xD;
        Refer to each respective Sub Protocol for additional exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hearn J Cho, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Multiple Myeloma Research Consortium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Auclair, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Multiple Myeloma Research Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Larsen, MD</last_name>
      <phone>480-809-9349</phone>
      <email>larsen.jeremy@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitya Nathwani, MD</last_name>
      <phone>626-256-4673</phone>
      <email>nnathwani@coh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Hofmeister, MD, MPH</last_name>
      <phone>404-778-0519</phone>
      <email>craig.hofmeister@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Yee, MD</last_name>
      <phone>617-219-1230</phone>
      <email>ayee1@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Avigan, MD</last_name>
      <phone>617-667-9920</phone>
      <email>davigan@bidmc.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giada Bianchi, MD</last_name>
      <phone>617-732-5190</phone>
      <email>giada_bianchi@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Christine Ye, MD</last_name>
      <phone>734-647-8902</phone>
      <email>jchrisye@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Zonder, MD</last_name>
      <phone>800-527-6266</phone>
      <email>zonderj@karmanos.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaji Kumar, MD</last_name>
      <phone>507-284-2511</phone>
      <email>kumar.shaji@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Division of Medical Oncology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Vij, MD, MBA</last_name>
      <phone>314-454-8304</phone>
      <email>rvij@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noa Biran, MD</last_name>
      <phone>551-996-8704</phone>
      <email>Noa.Biran@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Richter, MD</last_name>
      <phone>212-241-7873</phone>
      <email>joshua.richter@mountsinai.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malin Hultcrantz, MD PhD</last_name>
      <phone>646-608-3714</phone>
      <email>hultcram@mskcc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Voorhees, MD</last_name>
      <phone>980-442-4363</phone>
      <email>peter.voorhees@atriumhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University College of Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Chaudhry, MBBS</last_name>
      <phone>614-293-3196</phone>
      <email>maria.chaudhry@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ankit Kansagra, MD</last_name>
      <phone>214-645-8300</phone>
      <email>ankit.kansagra@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30206-6/fulltext</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6. Review.</citation>
    <PMID>27511158</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Relapsed Refractory</keyword>
  <keyword>Multiple Myeloma Research Consortium (MMRC)</keyword>
  <keyword>Genomic Profile</keyword>
  <keyword>My Drug</keyword>
  <keyword>Multiple Myeloma Research Foundation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

